Sol-Gel Announced Signing of Six Exclusive License Agreements to Commercialize TWYNEO and EPSOLAY in Europe and South Africa
Portfolio Pulse from charles@benzinga.com
Sol-Gel Technologies (NASDAQ:SLGL) has signed six exclusive license agreements to commercialize its dermatology products TWYNEO and EPSOLAY in Europe and South Africa. The agreements include upfront and milestone payments, as well as future royalties.
July 25, 2024 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sol-Gel Technologies has entered into six exclusive license agreements to commercialize TWYNEO and EPSOLAY in Europe and South Africa. The agreements include upfront and milestone payments, as well as future royalties.
The signing of these agreements is likely to positively impact Sol-Gel's stock price in the short term due to the expected upfront payments, milestone payments, and future royalties. This expansion into new markets can drive revenue growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100